Michael L West
5PUBLICATIONS
26CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jan 10, 2026
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.Peter Nordbeck, Ozlem Goker-Alpan, John A Bernat
|Oct 17, 2023
Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy.Christiane Auray-Blais, Pamela Lavoie, Tristan Martineau
|Aug 26, 2022
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease.Markus Cybulla, Kathleen Nicholls, Sandro Feriozzi
|Sep 20, 2021
The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.Aneal Khan, Sandra M Sirrs, Daniel G Bichet
|Nov 22, 2019
Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.Uma Ramaswami, Michael Beck, Derralynn Hughes
Pageof 1
Frequent Collaborators
3 joint publications
Kathy Nicholls
1 joint publications
Guillem Pintos-Morell
1 joint publications
Roberto Giugliani
1 joint publications
Markus Cybulla
1 joint publications
Sandro Feriozzi
1 joint publications
Joan Torras
1 joint publications
Bojan Vujkovac
1 joint publications
Christiane Auray-Blais
1 joint publications
Pamela Lavoie
1 joint publications
Tristan Martineau
